Rhubarb

Rhubarb Bio is a biotechnology company focused on developing novel therapeutics that leverage chaperone-mediated autophagy (CMA) to treat diseases driven by protein aggregation and cellular stress. Founded by Atlas Venture, the company aims to modulate the CMA pathway, specifically targeting the LAMP2A receptor to enhance the selective degradation of toxic proteins. Their approach has potential applications across a range of therapeutic areas, including neurodegeneration, metabolic disorders, and oncology. By restoring or enhancing this natural cellular cleaning process, Rhubarb Bio seeks to provide transformative treatments for conditions with high unmet medical needs. The company operates at the intersection of lysosomal biology and protein homeostasis, utilizing a proprietary platform to identify small molecule modulators of CMA.